0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Protein > FGF-21 > FG1-H5243

Human FGF-21 Protein, His Tag

Order Now

  • Synonyme
    FGF-21, FGF21
  • Source
    Human FGF-21, His Tag (FG1-H5243) is expressed from human 293 cells (HEK293). It contains AA His 29 - Ser 209 (Accession # Q9NSA1-1).
    Predicted N-terminus: His
  • Caractérisation moléculaire
    Online(His 29 - Ser 209) Q9NSA1-1

    This protein carries a polyhistidine tag at the N-terminus.

    The protein has a calculated MW of 21.3 kDa. The protein migrates as 25-28 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxine
    Less than 1.0 EU per μg by the LAL method.
  • Pureté

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Stockage:

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Human FGF-21, His Tag (Cat. No. FG1-H5243) SDS-PAGE gel

Human FGF-21, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

  • CONTEXTE
    Fibroblast growth factor 21 (FGF21), which stimulates glucose uptake in differentiated adipocytes via the induction of glucose transporter SLC2A1/GLUT1 expression. FGF21 has been shown to protect animals from diet-induced obesity when overexpressed in transgenic mice. It also lowers blood glucose and triglyceride levels when administered to diabetic rodents, suggesting it may exhibit the therapeutic characteristics necessary for effective treatment of diabetes. Treatment of animals with FGF21 results in increased energy expenditure, fat utilisation and lipid excretion. FGF21 is most abundantly expressed in the liver, and also expressed in the thymus at lower levels.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)


ETA des produits en stock: 2 jours ouvrables

Price(EUR) : €220.00

Price(EUR) : €2000.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:8 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Laisser un message